Avalo Therapeutics stock analysis
Want to see AVTX full AI Analyst Report?
Avalo Therapeutics (AVTX) Stock Price & Analysis
AVTX Stock Chart & Stats
- Day’s Range
- $6.68 - $7.18
- 52-Week Range
- $6.53 - $24.27
- Previous Close
- $7.13
- Volume
- N/A
- Average Volume (3M)
- 2.65M
- Market Cap
- $412.28M
- Enterprise Value
- $453.05M
- Total Cash (Recent Filing)
- $392.97M
- Total Debt (Recent Filing)
- $153.00K
- Price to Earnings (P/E)
- ―
- Beta
- 1.50
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- -0.45
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Essentially no reported debt limits near-term interest and refinancing burdens, giving Avalo greater financial flexibility than a similarly loss-making biotech with leverage. This supports continued development spending, although ongoing losses could still require future financing.
Equity Capital Base
The substantial equity base provides a current balance-sheet cushion and reduces dependence on creditors for funding. That support can help sustain clinical programs over the medium term, though the company’s history of equity swings highlights that this strength may depend on financing activity.
Development Pipeline
A focused pipeline across biologic and small-molecule programs gives Avalo multiple potential development paths in immune-mediated and inflammatory diseases. Success could create future product or partnering opportunities, although these candidates remain investigational and are not yet commercial products.
Bears Say
Minimal Revenue
The collapse to roughly $59K of revenue shows that Avalo currently has little recurring commercial activity to support its cost base. This leaves the company dependent on clinical progress and future commercialization or partnering rather than internally generated operating revenue.
Persistent Losses
Large and persistent losses indicate that the current business model is not yet producing earnings power. With expenses vastly above revenue, Avalo has limited capacity to self-fund development, making future financial performance highly dependent on successful pipeline advancement.
Cash Burn And Funding Risk
Sustained negative free cash flow requires external funding to maintain operations, while the new stock-sales agreement provides a mechanism for additional equity financing. Potential issuance can support development but may increase dilution pressure and reflects continuing funding needs.
Avalo Therapeutics News
AVTX FAQ
What was Avalo Therapeutics’s price range in the past 12 months?
What is Avalo Therapeutics’s market cap?
When is Avalo Therapeutics’s upcoming earnings report date?
How were Avalo Therapeutics’s earnings last quarter?
Is Avalo Therapeutics overvalued?
Does Avalo Therapeutics pay dividends?
What is Avalo Therapeutics’s EPS estimate?
How many shares outstanding does Avalo Therapeutics have?
What happened to Avalo Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Avalo Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Avalo Therapeutics Stock Smart Score
Company Description
Avalo Therapeutics
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Garry A. Neil
- Employees
- 33
- Website
- www.avalotx.com
- Address
- 1500 Liberty Ridge Drive, Wayne, PA, 19087, US
Avalo Therapeutics (AVTX) Earnings & Revenues
AVTX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 6 | 14 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 0 | 0 | 12 |











